Safety of Combined Aripiprazole and Risperidone Therapy

Guidelines on Antipsychotic Polypharmacy

Most clinical guidelines recommend antipsychotic monotherapy as the preferred approach for treating psychotic disorders 1, 2.
The National Institute for Health and Care Excellence (NICE) advises against regular combined antipsychotic medication except for short periods when changing medications 1.
The World Federation of Societies of Biological Psychiatry guidelines only recommend considering antipsychotic polypharmacy in specific cases like treatment-resistant schizophrenia 1.
The American Psychiatric Association guidelines endorse monotherapy and do not acknowledge situations where antipsychotic polypharmacy would be recommended 1.

Both medications are antipsychotics that work through dopamine receptor modulation, but with different mechanisms - aripiprazole is a partial D2 agonist while risperidone is a D2 antagonist 3, 4.
This combination may lead to increased extrapyramidal symptoms (EPS) due to additive effects on dopamine receptors 3, 4.
This combination may lead to a higher global side-effect burden, including increased risk of Parkinsonian side effects 3.
This combination may lead to potential cognitive impairment, though this may be related to higher total antipsychotic dosing rather than polypharmacy itself 4.

For treatment-resistant schizophrenia where clozapine monotherapy has failed, adding a second antipsychotic might be considered 1.
When managing medication side effects, particularly when aripiprazole is added to counteract metabolic or prolactin-related side effects of other antipsychotics 3.
During cross-titration periods when switching from one antipsychotic to another 1.

If antipsychotic monotherapy is ineffective, consider optimizing the dose of a single agent before adding a second antipsychotic 4.
If polypharmacy is deemed necessary, select antipsychotics with differing side-effect profiles to minimize additive adverse effects 3.
Monitor closely for extrapyramidal symptoms 3, 4.
Monitor closely for metabolic effects 3.
Monitor closely for drug-drug interactions affecting plasma concentrations 4.

Aripiprazole augmentation has demonstrated beneficial effects for reduced hyperprolactinemia and sexual dysfunction when combined with antipsychotics that have greater side-effect burden, according to the Endocrine Society 5

Exclude macroprolactinemia by requesting serial dilutions, as this accounts for 10-40% of hyperprolactinemia cases and requires no treatment, as recommended by the Endocrine Society 6
Review all medications for other prolactin-elevating agents beyond risperidone, following guidelines from the Endocrine Society 6
Consider pituitary imaging if prolactin remains >200 ng/mL (approximately 4000 mIU/L) despite medication adjustment, as this suggests possible prolactinoma, according to the Endocrine Society 6

If the patient has treatment-resistant psychosis requiring clozapine, consider switching to clozapine monotherapy rather than continuing risperidone-aripiprazole combination long-term, as suggested by the American Psychiatric Association 7
Watch for metabolic effects, though aripiprazole typically improves rather than worsens metabolic parameters, according to the National Institute of Mental Health 5